PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
PUMA BIOTECHNOLOGY, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.21+0.38 (+3.87%)
Close on Oct 19, 2026
- Market cap
- $537.01M
- P/E (TTM)
- 19.6
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
74.5%−8.0 pts over 5 years
Operating margin
16.3%+29.8 pts over 5 years
Net margin
13.6%+40.3 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -0.9% | +0.0% | +0.3% | – | |
| Gross profit | +2.5% | -0.5% | -1.7% | – | |
| Operating income | +20.5% | +16.3% | – | – | |
| Net income | +2.8% | +2396.3% | – | – | |
| EPS, diluted | -1.6% | – | – | – | |
| Free cash flow | +7.4% | – | +124.8% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -132.8% | -1042.3% | 28.0% | |
| Return on assets | -112.1% | -25.0% | 14.5% | |
| Current ratio | 6.31 | 1.28 | 2.00 | |
| Debt to equity | – | -16.52 | 0.17 | |
| Net debt to EBITDA | – | -0.64× | -0.15× | |
| Interest coverage | – | -2.2× | 5.6× | |
| Inventory turnover | – | 11.9× | 8.2× | |
| Capex to revenue | – | 0.0% | 0.0% | |
| Diluted shares | 33M | 40M | 51M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Puma Biotechnology generated $144.21M from operations and spent $267.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$144.21M
Used
$267.00K
Capital expenditure$267.00K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin13.6%
×Asset turnover1.06×
×Equity multiplier1.93×
=Return on equity, FY202528.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 13.6% | 1.06× | 1.93× | 28.0% |
| FY2024 | 13.1% | 1.04× | 3.05× | 41.6% |
| FY2023 | 9.2% | 1.04× | 6.03× | 57.5% |
| FY2022 | 0.0% | 1.02× | 23.41× | 0.0% |
| FY2021 | -11.5% | 1.08× | -56.07× | 693.7% |
| FY2020 | -26.7% | 0.94× | 41.62× | -1042.3% |
| FY2019 | -27.8% | 1.10× | 9.54× | -292.0% |
| FY2018 | -45.3% | 1.18× | 4.85× | -259.3% |
| FY2017 | -1054.6% | 0.13× | 1.59× | -221.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
8of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$31.11M
- Cash generatingOperating cash flow above zero$41.80M
- Return on assets improvedROA up on the prior year13.1% → 14.6%
- Earnings backed by cashOperating cash flow above net income$41.80M vs $31.11M
- Less leverageLong-term debt to assets fell10.2% → 0.0%
- Better liquidityCurrent ratio rose1.54 → 2.00
- No dilutionShare count did not rise49M → 51M
- Gross margin improvedGross margin up on the prior year72.06% → 74.53%
- More efficientAsset turnover rose1.00 → 1.07